. | MGMTp classification based on cutoff of 1.27 . | |||||||
---|---|---|---|---|---|---|---|---|
. | Nordic/NOA8/RT . | Nordic/NOA8/TMZ . | CE.6/RT . | CE6/RT + TMZ . | ||||
MGMTp status (original procedure and cutoff, 1) . | Unmethylated (N = 105) . | Methylated (N = 91) . | Unmethylated (N = 87) . | Methylated (N = 46) . | Unmethylated (N = 91) . | Methylated (N = 84) . | Unmethylated (N = 85) . | Methylated (N = 98) . |
Unmethylated | 103 (98.1%) | 5 (5.5%) | 86 (98.9%) | 0 (0%) | 89 (97.8%) | 7 (8.3%) | 85 (100%) | 8 (8.2%) |
Methylated | 2 (1.9%) | 86 (94.5%) | 1 (1.1%) | 46 (100%) | 2 (2.2%) | 77 (91.7%) | 0 (0%) | 90 (91.8%) |
Kappa (95% CI) | 0.93 (0.86–0.97) | 0.98 (0.92–1.00) | 0.90 (0.81–0.95) | 0.91 (0.83–0.96) |
. | MGMTp classification based on cutoff of 1.27 . | |||||||
---|---|---|---|---|---|---|---|---|
. | Nordic/NOA8/RT . | Nordic/NOA8/TMZ . | CE.6/RT . | CE6/RT + TMZ . | ||||
MGMTp status (original procedure and cutoff, 1) . | Unmethylated (N = 105) . | Methylated (N = 91) . | Unmethylated (N = 87) . | Methylated (N = 46) . | Unmethylated (N = 91) . | Methylated (N = 84) . | Unmethylated (N = 85) . | Methylated (N = 98) . |
Unmethylated | 103 (98.1%) | 5 (5.5%) | 86 (98.9%) | 0 (0%) | 89 (97.8%) | 7 (8.3%) | 85 (100%) | 8 (8.2%) |
Methylated | 2 (1.9%) | 86 (94.5%) | 1 (1.1%) | 46 (100%) | 2 (2.2%) | 77 (91.7%) | 0 (0%) | 90 (91.8%) |
Kappa (95% CI) | 0.93 (0.86–0.97) | 0.98 (0.92–1.00) | 0.90 (0.81–0.95) | 0.91 (0.83–0.96) |
. | MGMTp classification based on cutoff of 1.27 . | |||||||
---|---|---|---|---|---|---|---|---|
. | Nordic/NOA8/RT . | Nordic/NOA8/TMZ . | CE.6/RT . | CE6/RT + TMZ . | ||||
MGMTp status (original procedure and cutoff, 1) . | Unmethylated (N = 105) . | Methylated (N = 91) . | Unmethylated (N = 87) . | Methylated (N = 46) . | Unmethylated (N = 91) . | Methylated (N = 84) . | Unmethylated (N = 85) . | Methylated (N = 98) . |
Unmethylated | 103 (98.1%) | 5 (5.5%) | 86 (98.9%) | 0 (0%) | 89 (97.8%) | 7 (8.3%) | 85 (100%) | 8 (8.2%) |
Methylated | 2 (1.9%) | 86 (94.5%) | 1 (1.1%) | 46 (100%) | 2 (2.2%) | 77 (91.7%) | 0 (0%) | 90 (91.8%) |
Kappa (95% CI) | 0.93 (0.86–0.97) | 0.98 (0.92–1.00) | 0.90 (0.81–0.95) | 0.91 (0.83–0.96) |
. | MGMTp classification based on cutoff of 1.27 . | |||||||
---|---|---|---|---|---|---|---|---|
. | Nordic/NOA8/RT . | Nordic/NOA8/TMZ . | CE.6/RT . | CE6/RT + TMZ . | ||||
MGMTp status (original procedure and cutoff, 1) . | Unmethylated (N = 105) . | Methylated (N = 91) . | Unmethylated (N = 87) . | Methylated (N = 46) . | Unmethylated (N = 91) . | Methylated (N = 84) . | Unmethylated (N = 85) . | Methylated (N = 98) . |
Unmethylated | 103 (98.1%) | 5 (5.5%) | 86 (98.9%) | 0 (0%) | 89 (97.8%) | 7 (8.3%) | 85 (100%) | 8 (8.2%) |
Methylated | 2 (1.9%) | 86 (94.5%) | 1 (1.1%) | 46 (100%) | 2 (2.2%) | 77 (91.7%) | 0 (0%) | 90 (91.8%) |
Kappa (95% CI) | 0.93 (0.86–0.97) | 0.98 (0.92–1.00) | 0.90 (0.81–0.95) | 0.91 (0.83–0.96) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.